Coherus BioSciences, Inc., a biosimilar company, develops and commercializes various therapeutic products worldwide. The company engages in the development of late-stage clinical products, including CHS-1701 pegfilgrastim biosimilar, a granulocyte colony-stimulating factor product candidate; CHS-1420 adalimumab biosimilar, an anti-tumor necrosis factor product candidate; and CHS-0214, an etanercept biosimilar for rheumatoid arthritis and psoriasis. It is also developing a pipeline of products in therapeutic areas, such as oncology, immunology, and ophthalmology comprising CHS-3351, a ranibizumab biosimilar; and CHS-2020, an aflibercept biosimilar, as well as CHS-131, a small molecule for multiple sclerosis. Coherus BioSciences, Inc. has license agreement with Selexis SA and Genentech, Inc. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CHRS
Previous Symbol
CUSIPN/A
Phone650-649-3530
Debt
Debt-to-Equity Ratio8.29
Current Ratio5.31
Quick Ratio5.31
Price-To-Earnings
Trailing P/E Ratio-2.22
Forward P/E Ratio-3.19
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.56 million
Price / Sales433.91
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.51 per share
Price / Book19.51
Profitability
EPS (Most Recent Fiscal Year)($4.48)
Net Income$-238,170,000.00
Net MarginsN/A
Return on Equity-770.38%
Return on Assets-126.16%
Miscellaneous
Employees122
Outstanding Shares68,030,000
Market Cap$710.18 million
OptionableOptionable
Coherus Biosciences (NASDAQ:CHRS) Frequently Asked Questions
What is Coherus Biosciences' stock symbol?
Coherus Biosciences trades on the NASDAQ under the ticker symbol "CHRS."
How were Coherus Biosciences' earnings last quarter?
Coherus Biosciences Inc (NASDAQ:CHRS) issued its quarterly earnings results on Thursday, November, 8th. The biotechnology company reported ($0.87) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.79) by $0.08. View Coherus Biosciences' Earnings History.
When is Coherus Biosciences' next earnings date?
What price target have analysts set for CHRS?
4 brokers have issued 1-year price objectives for Coherus Biosciences' stock. Their forecasts range from $25.00 to $45.00. On average, they expect Coherus Biosciences' share price to reach $30.75 in the next twelve months. This suggests a possible upside of 209.0% from the stock's current price. View Analyst Price Targets for Coherus Biosciences.
What is the consensus analysts' recommendation for Coherus Biosciences?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Coherus Biosciences in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Coherus Biosciences.
What are Wall Street analysts saying about Coherus Biosciences stock?
Here are some recent quotes from research analysts about Coherus Biosciences stock:
- 1. According to Zacks Investment Research, "Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Coherus Biosciences, Inc. is headquartered in Redwood City, California. " (12/10/2018)
- 2. Maxim Group analysts commented, "Coherus announced that UDENYCA (Neulasta biosimilar) has been granted marketing authorization by the European Commission (EC). Not surprising given that advancing biosimilars to approvals in the EU has been in our view, less challenging. Overall, very good news for Coherus. UDENYCA is also under review in the US (BSUFA 11/3/18) which is a significant catalyst for CHRS shares." (9/25/2018)
Has Coherus Biosciences been receiving favorable news coverage?
Media stories about CHRS stock have been trending somewhat positive recently, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Coherus Biosciences earned a media sentiment score of 1.5 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days.
Are investors shorting Coherus Biosciences?
Coherus Biosciences saw a increase in short interest in November. As of November 15th, there was short interest totalling 8,059,501 shares, an increase of 21.2% from the October 31st total of 6,650,469 shares. Based on an average daily trading volume, of 1,410,008 shares, the short-interest ratio is currently 5.7 days. Currently, 14.2% of the company's shares are short sold. View Coherus Biosciences' Current Options Chain.
Who are some of Coherus Biosciences' key competitors?
Some companies that are related to Coherus Biosciences include Repligen (RGEN), China Biologic Products (CBPO), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Regenxbio (RGNX), Denali Therapeutics (DNLI), Atara Biotherapeutics (ATRA), Crispr Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), Rubius Therapeutics (RUBY), Spark Therapeutics (ONCE), Autolus Therapeutics (AUTL), Editas Medicine (EDIT), Orchard Therapeutics (ORTX) and Sangamo Therapeutics (SGMO).
Who are Coherus Biosciences' key executives?
Coherus Biosciences' management team includes the folowing people:
- Mr. Dennis M. Lanfear, Chairman, Pres & CEO (Age 63)
- Dr. Jean-Frédéric Viret, Chief Financial Officer (Age 52)
- Dr. Peter K. Watler, Chief Technical Officer (Age 56)
- Dr. Barbara K. Finck, Chief Medical Officer (Age 71)
- Dr. V. Bryan Lawlis Jr., Science Director, Director & Member of Supervisory Board (Age 66)
Who are Coherus Biosciences' major shareholders?
Coherus Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (9.53%), BlackRock Inc. (6.82%), Sofinnova Ventures Inc (4.22%), Vanguard Group Inc. (3.94%), Hound Partners LLC (2.95%) and Deutsche Bank AG (2.68%). Company insiders that own Coherus Biosciences stock include Alan C Herman, Barbara K Finck, Dennis M Lanfear, James Healy and Jean-Frederic Viret. View Institutional Ownership Trends for Coherus Biosciences.
Which major investors are selling Coherus Biosciences stock?
CHRS stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., FMR LLC, Morgan Stanley, Point72 Asset Management L.P., Tekla Capital Management LLC, Highland Capital Management LP, Rubric Capital Management LP and C WorldWide Group Holding A S. Company insiders that have sold Coherus Biosciences company stock in the last year include Barbara K Finck, Dennis M Lanfear, James Healy and Jean-Frederic Viret. View Insider Buying and Selling for Coherus Biosciences.
Which major investors are buying Coherus Biosciences stock?
CHRS stock was acquired by a variety of institutional investors in the last quarter, including Hound Partners LLC, Deutsche Bank AG, BlackRock Inc., Vanguard Group Inc., Marshall Wace LLP, Trexquant Investment LP, Mirae Asset Global Investments Co. Ltd. and TIAA CREF Investment Management LLC. View Insider Buying and Selling for Coherus Biosciences.
How do I buy shares of Coherus Biosciences?
Shares of CHRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Coherus Biosciences' stock price today?
One share of CHRS stock can currently be purchased for approximately $9.95.
How big of a company is Coherus Biosciences?
Coherus Biosciences has a market capitalization of $710.18 million and generates $1.56 million in revenue each year. The biotechnology company earns $-238,170,000.00 in net income (profit) each year or ($4.48) on an earnings per share basis. Coherus Biosciences employs 122 workers across the globe.
What is Coherus Biosciences' official website?
How can I contact Coherus Biosciences?
Coherus Biosciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The biotechnology company can be reached via phone at 650-649-3530 or via email at [email protected]
MarketBeat Community Rating for Coherus Biosciences (NASDAQ CHRS)
MarketBeat's community ratings are surveys of what our community members think about Coherus Biosciences and other stocks. Vote "Outperform" if you believe CHRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CHRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
